Tag Archives: Patent Law

Wyeth v. Abbott Labs. – Picking Plaintiff’s Poison

Posted on June 28, 2013 by Warren Woessner

In July of 2011, I wrote a post for this blog on BSC v. J&J, a Fed. Cir. decision in which four J&J patents claiming stents eluting rapamycin, a drug that inhibits restenosis after balloon angioplasty, were held invalid for … Continue reading →

Posted in Enablement, Written Description Requirements (WDR) | Tagged , , , , , , , , , , | 1 Comment

Finally, A Reasonable Decision

Posted on June 24, 2013 by Warren Woessner

This is a guest post from Greg Stark, attorney at Schwegman Lundberg & Woessner. Attached at the end of this post is an annotated copy of the June 21st decision from the Federal Circuit in Ultramercial v. Hulu. The underlying patent … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | Leave a comment

Can AMP v. Myriad Revive Diagnostic Method Claims?

Posted on June 17, 2013 by Warren Woessner

At the end of the Supreme Court’s Opinion, Justice Thomas makes it clear that the Court was impressed by Judge Byson’s dissents in the Fed. Cir. Myriad opinions. Although Judge Bryson was on the Intema panel that sank claims to … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , | 4 Comments

Association For Molecular Pathology V Myriad Genetics – An Isolated Local Difficulty?

Posted on June 14, 2013 by Warren Woessner

Paul Cole, Professor of Intellectual Property Law at Bournemouth University and European Patent Attorney at Lucas & Co, Warlingham, Surrey, UK discusses yesterdays Myriad ruling by the Supreme Court. How does yesterday’s Supreme Court decision match international opinion on the patentability … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | Leave a comment